Oof_老虎社区_美港股上老虎

Jingting98
2021-07-21

Oof

Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study

JNJ says data from study 'do not speak to the full nature of immune protection'. The one-shot coron

Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":176056948,"tweetId":"176056948","gmtCreate":1626848478284,"gmtModify":1631889995353,"author":{"id":3586824800816197,"idStr":"3586824800816197","authorId":3586824800816197,"authorIdStr":"3586824800816197","name":"Jingting98","avatar":"https://static.tigerbbs.com/59173463f34df49803eb7faf01738a6a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Oof&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Oof&nbsp;</p></body></html>","text":"Oof","highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/176056948","repostId":2153866611,"repostType":4,"repost":{"id":"2153866611","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1626847800,"share":"https://www.laohu8.com/m/news/2153866611?lang=&edition=full","pubTime":"2021-07-21 14:10","market":"us","language":"en","title":"Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study","url":"https://stock-news.laohu8.com/highlight/detail?id=2153866611","media":"Dow Jones","summary":"JNJ says data from study 'do not speak to the full nature of immune protection'.\n\nThe one-shot coron","content":"<blockquote>\n JNJ says data from study 'do not speak to the full nature of immune protection'.\n</blockquote>\n<p>The <a href=\"https://laohu8.com/S/AONE.U\">one</a>-shot coronavirus vaccine from Johnson &amp; Johnson is much less effective against the Delta variant than it is against the original version of COVID-19, according to a new study posted online Tuesday.</p>\n<p>The study, which examined blood samples in a laboratory setting and has not yet been peer-reviewed, suggests that anyone who received the J&amp;J <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine may need to receive a second shot as the variant continues to spread across the US.</p>\n<p>\"The message that we wanted to give was not that people shouldn't get the J&amp;J vaccine, but we hope that in the future, it will be boosted with either another dose of J&amp;J or a boost with Pfizer or Moderna,\" study leader Nathaniel Landau, a virologist at NYU's Grossman School of Medicine, told The New York Times .</p>\n<p>Earlier this month, New Jersey-based Johnson &amp; Johnson published preliminary data indicating its vaccine was effective against the Delta variant, first located in India, at least eight months after inoculation.</p>\n<p>However, in May, the British government released a study vaccine, which is similar in structure to the Johnson &amp; Johnson vaccine, was just 33 percent effective against \"symptomatic disease\" caused by the Delta variant, while two doses were 60 percent effective against symptomatic disease.</p>\n<p>J&amp;J spokesperson Seema Kumar told the Times that the data from the latest study \"do not speak to the full nature of immune protection.\"</p>\n<p>Last month, Centers for Disease Control and Prevention <a href=\"https://laohu8.com/S/CDC\">$(CDC)$</a> Director Dr. Rochelle Walensky told NBC's \"Today\" show that \"we have every reason to believe ... that the J&amp;J will perform well against the Delta variant, as it has so far against other variants circulating in the United States.\"</p>\n<p>Walensky told lawmakers earlier Tuesday that the Delta variant currently accounts for 83 percent of all COVID-19 cases in the US. During the same hearing, White House chief medical adviser Dr. Anthony Fauci said researchers were still assessing whether booster shots would be needed to provide additional protection.</p>\n<p>\"We don't want people to believe that when you're talking about boosters, that means the vaccines aren't effective,\" Fauci said. \"They are highly effective, we are talking about the durability of that.\"</p>\n<p>Initial studies indicate that mRNA vaccines manufactured by Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> and Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> are effective against the Delta variant and could provide protection for years, provided the virus doesn't mutate far beyond its initial form.</p>\n<p>The Delta variant has been blamed for an increase in cases, hospitalizations and deaths in recent weeks, though the numbers in all categories are still well below the peak of last winter's surge and the overwhelming majority of hospitalizations and deaths are occurring among unvaccinated people.</p>\n<p>Despite that, health officials in Los Angeles and Las Vegas have reimposed mask mandates in indoor spaces, regardless of individuals' vaccination status.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-07-21 14:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n JNJ says data from study 'do not speak to the full nature of immune protection'.\n</blockquote>\n<p>The <a href=\"https://laohu8.com/S/AONE.U\">one</a>-shot coronavirus vaccine from Johnson &amp; Johnson is much less effective against the Delta variant than it is against the original version of COVID-19, according to a new study posted online Tuesday.</p>\n<p>The study, which examined blood samples in a laboratory setting and has not yet been peer-reviewed, suggests that anyone who received the J&amp;J <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine may need to receive a second shot as the variant continues to spread across the US.</p>\n<p>\"The message that we wanted to give was not that people shouldn't get the J&amp;J vaccine, but we hope that in the future, it will be boosted with either another dose of J&amp;J or a boost with Pfizer or Moderna,\" study leader Nathaniel Landau, a virologist at NYU's Grossman School of Medicine, told The New York Times .</p>\n<p>Earlier this month, New Jersey-based Johnson &amp; Johnson published preliminary data indicating its vaccine was effective against the Delta variant, first located in India, at least eight months after inoculation.</p>\n<p>However, in May, the British government released a study vaccine, which is similar in structure to the Johnson &amp; Johnson vaccine, was just 33 percent effective against \"symptomatic disease\" caused by the Delta variant, while two doses were 60 percent effective against symptomatic disease.</p>\n<p>J&amp;J spokesperson Seema Kumar told the Times that the data from the latest study \"do not speak to the full nature of immune protection.\"</p>\n<p>Last month, Centers for Disease Control and Prevention <a href=\"https://laohu8.com/S/CDC\">$(CDC)$</a> Director Dr. Rochelle Walensky told NBC's \"Today\" show that \"we have every reason to believe ... that the J&amp;J will perform well against the Delta variant, as it has so far against other variants circulating in the United States.\"</p>\n<p>Walensky told lawmakers earlier Tuesday that the Delta variant currently accounts for 83 percent of all COVID-19 cases in the US. During the same hearing, White House chief medical adviser Dr. Anthony Fauci said researchers were still assessing whether booster shots would be needed to provide additional protection.</p>\n<p>\"We don't want people to believe that when you're talking about boosters, that means the vaccines aren't effective,\" Fauci said. \"They are highly effective, we are talking about the durability of that.\"</p>\n<p>Initial studies indicate that mRNA vaccines manufactured by Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> and Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> are effective against the Delta variant and could provide protection for years, provided the virus doesn't mutate far beyond its initial form.</p>\n<p>The Delta variant has been blamed for an increase in cases, hospitalizations and deaths in recent weeks, though the numbers in all categories are still well below the peak of last winter's surge and the overwhelming majority of hospitalizations and deaths are occurring among unvaccinated people.</p>\n<p>Despite that, health officials in Los Angeles and Las Vegas have reimposed mask mandates in indoor spaces, regardless of individuals' vaccination status.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153866611","content_text":"JNJ says data from study 'do not speak to the full nature of immune protection'.\n\nThe one-shot coronavirus vaccine from Johnson & Johnson is much less effective against the Delta variant than it is against the original version of COVID-19, according to a new study posted online Tuesday.\nThe study, which examined blood samples in a laboratory setting and has not yet been peer-reviewed, suggests that anyone who received the J&J $(JNJ)$ vaccine may need to receive a second shot as the variant continues to spread across the US.\n\"The message that we wanted to give was not that people shouldn't get the J&J vaccine, but we hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna,\" study leader Nathaniel Landau, a virologist at NYU's Grossman School of Medicine, told The New York Times .\nEarlier this month, New Jersey-based Johnson & Johnson published preliminary data indicating its vaccine was effective against the Delta variant, first located in India, at least eight months after inoculation.\nHowever, in May, the British government released a study vaccine, which is similar in structure to the Johnson & Johnson vaccine, was just 33 percent effective against \"symptomatic disease\" caused by the Delta variant, while two doses were 60 percent effective against symptomatic disease.\nJ&J spokesperson Seema Kumar told the Times that the data from the latest study \"do not speak to the full nature of immune protection.\"\nLast month, Centers for Disease Control and Prevention $(CDC)$ Director Dr. Rochelle Walensky told NBC's \"Today\" show that \"we have every reason to believe ... that the J&J will perform well against the Delta variant, as it has so far against other variants circulating in the United States.\"\nWalensky told lawmakers earlier Tuesday that the Delta variant currently accounts for 83 percent of all COVID-19 cases in the US. During the same hearing, White House chief medical adviser Dr. Anthony Fauci said researchers were still assessing whether booster shots would be needed to provide additional protection.\n\"We don't want people to believe that when you're talking about boosters, that means the vaccines aren't effective,\" Fauci said. \"They are highly effective, we are talking about the durability of that.\"\nInitial studies indicate that mRNA vaccines manufactured by Moderna $(MRNA)$ and Pfizer $(PFE)$ BioNTech $(BNTX)$ are effective against the Delta variant and could provide protection for years, provided the virus doesn't mutate far beyond its initial form.\nThe Delta variant has been blamed for an increase in cases, hospitalizations and deaths in recent weeks, though the numbers in all categories are still well below the peak of last winter's surge and the overwhelming majority of hospitalizations and deaths are occurring among unvaccinated people.\nDespite that, health officials in Los Angeles and Las Vegas have reimposed mask mandates in indoor spaces, regardless of individuals' vaccination status.","news_type":1},"isVote":1,"tweetType":1,"viewCount":318,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says study

评论（1）

热议股票